Intellipharmaceutics International Inc. (IPCI)

[AngeloFoca]

Going by patent #
078908 - Teva - all doses except 25 30 and 35
202731 - TEVA - 30
078992 - IPCI - 15 and 30
202842 - PAR - All doses (8) -- only mfg. with 25 and 35 generic approved

Teva's 15 mg was submitted before IPCI but perhaps had an error that allowed IPCI to become 1st to file.

It appears that PAR submitted all doses same time although relatively later than TEVA and IPCI - so their interest was all along only in the 15 and 30 mg 180 day exclusivity.

I imagine down the road - sometime - all doses will have FDA approval and they can partner Focalin XR with Mallinckrodt.